Delcath Systems Granted NTAP Status For HEPZATO KIT By CMS, Effective October 1, 2024
Portfolio Pulse from Benzinga Newsdesk
Delcath Systems has been granted NTAP status for its HEPZATO KIT by the Centers for Medicare & Medicaid Services (CMS), effective October 1, 2024.
August 05, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Delcath Systems has received NTAP status for its HEPZATO KIT from CMS, which will be effective starting October 1, 2024. This status is likely to enhance the reimbursement landscape for the product, potentially boosting its adoption and sales.
The NTAP status from CMS is a significant regulatory milestone that can improve the reimbursement scenario for the HEPZATO KIT, making it more attractive to healthcare providers. This is likely to positively impact the sales and adoption of the product, thereby benefiting Delcath Systems' financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100